High reduction of circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin)
Titel:
High reduction of circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin)
Auteur:
Manso, L. Moreno, F. Delgado, J.I. Echarri, M.J. López, A. Izarzugaza, Y. Borrega, P. Martínez, N. Olier, C. Cortes-Funes, H.